This therapy achieved a CR rate of 90% which significantly surpassed those previously reported with tumor-targeted PIT and intratumoral IL-15 administration [19] or CD25-targeted NIR-PIT and systemic IL-15 administration [15] despite the reduced dose of IL-15. This evidence concerns the gene IL15 and neoplasm.